Suggested remit: To appraise the clinical and cost effectiveness of tisotumab vedotin within its marketing authorisation for treating recurrent or metastatic cervical cancer after chemotherapy.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Process:
- STA Standard
- ID number:
- 3753
Provisional Schedule
- Expected publication:
- 25 June 2026
Project Team
- Project lead
- Jennifer Upton
Email enquiries
If you have any queries please email [email protected]
Stakeholders
- Companies sponsors
- GenMAB a/s
- Others
- Department of Health and Social Care
- NHS England
- Welsh Government
- Professional groups
- Association of Cancer Physicians
- Cancer Research UK
- Royal College of Physicians
- Royal College of Radiologists (RCR)
- Associated public health groups
- Public Health Wales
- UK Health Security Agency (Formerly Public Health England)
- General commentators
- All Wales Therapeutics and Toxicology Centre
- British National Formulary (BNF)
- Department of Health - Northern Ireland
- Healthcare Improvement Scotland
- Medicines and Healthcare products Regulatory Agency
- NHS Wales Joint Commissioning Committee
- Scottish Medicines Consortium
- Welsh Government
- Relevant research groups
- Institute of Cancer Research
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 08 July 2025 | Invitation to participate |
| 07 May 2025 - 05 June 2025 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 3753 |
| 07 May 2025 | In progress. Scoping commencing |
| 23 July 2024 | Please note that following on from information received from the company the timelines have been revised to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early July 2025 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early September 2025. |
| 07 December 2023 | Please note that following on from advice received from the company this appraisal has been scheduled back into the work programme to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during early July 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately early September 2024. |
| 02 June 2020 | Following an update from the company the timelines for this appraisal are to be confirmed. Further information regarding the scheduling of the appraisal will be available in due course. |
For further information on our processes and methods, please see our CHTE processes and methods manual